Chief Investment Officer
Dr. Nadiia Wyttenbach
Responsibilities
-
Leads investment strategy and execution across sourcing, diligence, investment process, value creation and exits
-
Serves on boards, supporting portfolio companies in strategic growth and IPO/M&A readiness
Experience
17 years' combined experience across investing and molecular health
-
A decade in global investing and finance with multi-segment expertiseinvestment expertise: investment banking, listed equity, private equity buyouts, and growth/ venture capital
-
Six years in molecular medicine, applying digital and molecular tools (CNNs, RNA, CRISPR-Cas9, viral vectors, omics) to tackle obesity and metabolic disorders
Career Highlights:
-
Managing Director, Redalpine (Zurich, Switzerland)
-
Prior roles at Partners Group (private equity, healthcare), Kieger Asset Management (listed equity, buy-side), and boutique investment banking in Switzerland
-
Early career in Sartorius (bioprocessing,viral vectors) in Göttingen, Germany
Education
-
PhD in Molecular Health, ETH Zurich, Switzerland
-
MSc in Molecular Biology, Max Planck School / Georg-August University Göttingen, Germany
-
MBA, University of St. Gallen (HSG), Switzerland